16%. By Nick Paul Taylor Jul 12, 2023 8:57am. Jours fériés des marchés. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. We also use them to share usage. MONTREAL, Jan. : Renegotiated Lease to Generate Substantial Annual Savings. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Further. 00, suggesting a possible upside of. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Cookies are used to offer you a better browsing experience and to analyze our traffic. 124. 1-438. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Shares of Theratechnologies are up 4. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . com. 4. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. It is the Company’s proprietary peptide linked to. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. VANCOUVER, British Columbia, Nov. 5%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company was. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. 1300 (+9. Further. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. THTX | Complete Theratechnologies Inc. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. Stockhouse. Losses were -47. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. 03) EPS for the quarter, beating the consensus estimate of ($0. com. FAQ – Utilisateurs de TMX Argent NOUVEAU. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. 08). Investor Relations. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. 82 million. (“Theratechnologies”) with the Securities and Exchange Commission (the. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Image source: The Motley Fool. Stockhouse. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 20% from a day low at $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 4% from the stock's current price. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. 04) earnings per share (EPS) for the quarter. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. The reported ($0. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Theratechnologies Inc. Gary Littlejohn. TH 48% v4,15M c1. By continuing to use our service, you agree to our use of cookies. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | May 19, 2023. Stockhouse. com uses cookies on this site. Theratechnologies Inc. 5000 +0. 54% and a negative trailing twelve-month return on equity of 1,116. Headquarters. 86%. 35 as of 10:41 a. 86 million for the quarter. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. -based clinical sites participating in the conduct of the Phase. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. By continuing to use our service, you agree to our use of cookies. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. View real-time stock prices and stock quotes for a full financial overview. 9 million as at August 31, 2023. US Headquarters. Cookies are used to offer you a better browsing experience and to analyze our traffic. FDA for its IV push form of administration of Trogarzo. Further. stock price gained 1. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. . communications@theratech. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. MONTREAL, Sept. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. C. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. THERATECHNOLOGIES INC. Stockhouse. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage. lgibson. Theratechnologies Provides Details About R&D Day Webcast. Stockhouse. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. com uses cookies on this site. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. 00%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. NEW YORK, Dec. One reason for that is that this tier does not include penny stocks. (882) posted 3 minutes ago. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 617-356-1009. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A high-level overview of Theratechnologies Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. com. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Vice President, Communications and Corporate Affairs. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. 10% least volatile stocks in CA Market. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. home message. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Theratechnologies Inc. We also use them to share usage. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. 25 to $1. Senior Director, Communications & Corporate Affairs. 8. We also use them to share usage. com uses cookies on this site. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. The business had revenue of $27. 9 million and US$19. Cookies are used to offer you a better browsing experience and to analyze our traffic. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. (THTX) stock. com uses cookies on this site. 2% per year. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Theratechnologies Inc. Thank you. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. TH | September 5, 2023. . First Quarter Fiscal 2022 Financial Results. 3. MONTREAL, Feb. Data presented at AMCP Nexus 2023. M. 38. org. About TH1902. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Stockhouse. $30. com uses cookies on this site. THERATECHNOLOGIES INC. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies inc. 521. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. OTCQX – this is the premium tier of OTC stocks. The webinar will also address system-level barriers and present real-world. com uses cookies on this site. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Saint-Laurent, Canada. Stockhouse. GUD | Complete Knight Therapeutics Inc. com. communications@theratech. Learn why it. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. Their average twelve-month price target is $36. Marsolais’ presentation will be available through. ("Theratechnologies" or the "Company"). T. Once expert advice is considered, the Company. Montréal, Québec, Canada . About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. We also use them to share. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. We also use them to share usage. Market Cap. TH | May 19, 2023. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Elif McDonald - Senior Director, Investor Relations. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. S. 69 to $1. Stockhouse. Theratechnologies Appoints New Board Member. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About SORT1+ Technology™ and TH1902. Company Type For Profit. Share your ideas and get valuable. This news release constitutes a “designated news release” for the purposes. We also use them to share. Marsolais will present at the H. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. 2. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Senior Director, Communications & Corporate Affairs. FY2023 revenue guidance range set between $90 million and $95 million. com uses cookies on this site. com uses cookies on this site. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. 31K. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. La Bourse de Toronto a perdu. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Theratechnologies Inc. (2013-04-03 | TSX:TH) Theratechnologies Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. By continuing to use our service, you agree to our use of cookies. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 51 S1. Cookies are used to offer you a better browsing experience and to analyze our. View recently published Stock News reports from independent reports and journalists. European Headquarters. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. sBLA for F8 formulation of tesamorelin submitted to FDA. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. VANCOUVER, British Columbia, Nov. When this page refreshes you will be logged in with the new address. Follow. Stockhouse. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. By continuing to use our service, you agree to our use of cookies. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . T. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. Stockhouse. Theratechnologies . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies’ R&D staff is bearing the brunt of. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. Q3 2023 consolidated revenue of $20. The abstracts are now available at aacr. MONTREAL, Feb. acts as investment manager. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. We also use them to share usage information with our partners. View real-time stock prices and stock quotes for a full financial overview. Biopharmaceutical company Theratechnologies Inc. com uses cookies on this site. 33. 17% from a day low at $1. 67, which is an increase of 1,144. Following the release, Knight will hold a conference call and audio webcast. MONTREAL, Feb. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Theratechnologies Inc. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. com uses cookies on this site. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Investor Relations. Shares of Theratechnologies are up 4. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. com uses cookies on this site. 00 to $36. 49) by $0. Stockhouse. Cookies are used to offer you a better browsing experience and to. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. MONTREAL, Feb. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Cookies are used to offer you a better browsing experience and to analyze our traffic. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Stockhouse. MONTREAL, Aug. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Investor inquiries: Elif McDonald. Free cash flow. S. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. $103. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Cookies are used to offer you a better browsing experience and to analyze our traffic. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. By continuing to use our service, you agree to our use of cookies. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. MONTREAL, Feb. MONTREAL, Nov. 9 million and US. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Contact Email communications@theratech. Theratechnologies Inc. 9 million, adjusted EBITDA of $2. com uses cookies on this site. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Stockhouse. com. com uses cookies on this site. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. Theratechnologies. By continuing to use our service, you agree to our use of cookies. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. By continuing to use our service, you agree to our use of cookies. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. The price has fallen in 5 of the last 10 days. We currently market. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Phone Number (514) 336-7800. However, only about 4% of the stocks on the OTC market fall into this category. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Real-time discussion about Theratechnologies Inc. (THTX) NasdaqCM - NasdaqCM Real Time Price. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. Northwest also announces an update on its. By continuing to use our service, you agree to our use of cookies. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the.